Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
Laura Wood discusses the successful integration of avelumab, erdafitinib, and enfortumab vedotin-ejfv into oncology nursing practice.
Laura Wood on Multidisciplinary Collaboration for Managing Immunotherapy Adverse Events
Laura Wood on collaboration between departments when treating patients with cancer who are receiving immunotherapy treatments.
Laura Wood Discusses Immunotherapy Education Opportunities
Laura Wood explains the education opportunities available to nurses in the field of immunotherapy.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive Cranbury, NJ 08512